Miniature, Portable, Device to Detect and Monitor Coagulopathy Navy STTR FY2010.A Sol No.: Navy STTR FY2010.A Topic No.: N10A-T043 Topic Title: Miniature, Portable, Device to Detect and Monitor Coagulopathy Proposal No.: N10A-043-0364 Firm: HemoSonics, LLC 745 Walker Square, Suite 3C Charlottesville, Virginia 22903 Contact: Francesco Viola Phone: (434) 409-6281 Web Site: www.hemosonics.com Abstract: Trauma is a leading cause of both military and civilian mortality, accounting for roughly 10% of all deaths worldwide. Coagulopathy (disturbance of the physiologic balance between bleeding and clotting) is observed in 25% to 36% of trauma patients and significantly increases mortality. Trauma-related coagulopathy typically involves dysfunction or depletion of coagulation factors, platelets, fibrinogen, and fibrinolysis. Each of these defects requires specific treatment to correct, while improper treatment consumes time, money, and limited resources, and worsens outcomes. Proper trauma treatment requires the rapid assessment of hemostatic state. The ideal test is performed at the point of care, is robust to environmental vibration, takes only a few minutes to perform, specifies the exact hemostatic defect(s), is easy to use, and presents easy to interpret results. Unfortunately, no commercially available test or combination of tests meets these criteria. Under this proposal HemoSonics will test the applicability of its proprietary Sonorheometry technology to assess coagulopathy at the point of care. We will assess potential technical barriers and validate our approach to this critical health care problem. Success in Phase I will pave the way to a Phase II award and product commercialization. Benefits: If successful this research program will lead to a new paradigm for the assessment and management of coagulopathy. Given that inappropriate bleeding and coagulation are responsible for over 30% of deaths in the developed world, the potential to save life is enormous. HemoSonics estimates that the market for the product developed under this proposal exceeds $500m annually. Return